AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety Abatacept Compared to Placebo in Hospitalized Participant

Grants and Contracts Details


The purpose of this research is to gather information to see if a drug, abatacept, can help people recover from myocarditis due to an immune checkpoint inhibitor.
Effective start/end date12/6/2210/4/24


  • Massachusetts General Hospital: $34,043.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.